全文获取类型
收费全文 | 35595篇 |
免费 | 2308篇 |
国内免费 | 242篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 672篇 |
妇产科学 | 717篇 |
基础医学 | 4913篇 |
口腔科学 | 1691篇 |
临床医学 | 3004篇 |
内科学 | 8542篇 |
皮肤病学 | 585篇 |
神经病学 | 3340篇 |
特种医学 | 1031篇 |
外国民族医学 | 1篇 |
外科学 | 4804篇 |
综合类 | 170篇 |
一般理论 | 9篇 |
预防医学 | 2558篇 |
眼科学 | 523篇 |
药学 | 3051篇 |
中国医学 | 182篇 |
肿瘤学 | 1962篇 |
出版年
2023年 | 214篇 |
2022年 | 246篇 |
2021年 | 1070篇 |
2020年 | 713篇 |
2019年 | 923篇 |
2018年 | 1151篇 |
2017年 | 840篇 |
2016年 | 933篇 |
2015年 | 1073篇 |
2014年 | 1375篇 |
2013年 | 1779篇 |
2012年 | 2599篇 |
2011年 | 2712篇 |
2010年 | 1506篇 |
2009年 | 1340篇 |
2008年 | 2110篇 |
2007年 | 2182篇 |
2006年 | 1924篇 |
2005年 | 1931篇 |
2004年 | 1727篇 |
2003年 | 1557篇 |
2002年 | 1444篇 |
2001年 | 640篇 |
2000年 | 611篇 |
1999年 | 535篇 |
1998年 | 338篇 |
1997年 | 254篇 |
1996年 | 200篇 |
1995年 | 192篇 |
1994年 | 174篇 |
1993年 | 165篇 |
1992年 | 357篇 |
1991年 | 285篇 |
1990年 | 272篇 |
1989年 | 215篇 |
1988年 | 205篇 |
1987年 | 162篇 |
1986年 | 189篇 |
1985年 | 157篇 |
1984年 | 133篇 |
1983年 | 104篇 |
1982年 | 94篇 |
1981年 | 79篇 |
1980年 | 78篇 |
1979年 | 112篇 |
1978年 | 68篇 |
1977年 | 64篇 |
1975年 | 66篇 |
1974年 | 66篇 |
1973年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 26 毫秒
991.
992.
Amorim dos Santos Juliana Normando Ana Gabriela Costa de Toledo Isabela Porto Melo Gilberto De Luca Canto Graziela Santos-Silva Alan Roger Guerra Eliete Neves Silva 《Clinical oral investigations》2020,24(1):37-45
Clinical Oral Investigations - To evaluate therapeutic effects of laser therapy on patients with recurrent aphthous stomatitis assessing evidences from previously published systematic reviews. An... 相似文献
993.
Bordini Ester Alves Ferreira Cassiano Fernanda Balestrero Silva Isabela Sanches Pompeo Usberti Felipe Rochelle Anovazzi Giovana Pacheco Leandro Edgar Pansani Tasa Nogueira Leite Maria Lusa Hebling Josimeri de Souza Costa Carlos Alberto Soares Diana Gabriela 《Clinical oral investigations》2020,24(2):663-674
Clinical Oral Investigations - This study aimed to develop a porous chitosan–calcium–aluminate scaffold (CH-AlCa) in combination with a bioactive dosage of 1α,25-dihydroxyvitamin... 相似文献
994.
995.
Effectiveness of a protocol for teaching dental tooth color in students with color vision impairment
996.
997.
Alzheimer’s disease (AD) is a neurodegenerative process that inexorably leads to progressive deterioration of cognition function and, ultimately, death. Central pathophysiologic features of AD include the accumulation of extracellular plaques comprised of amyloid-β peptide (Aβ) and the presence of intraneuronal neurofibrillary tangles. However, a large body of evidence suggests that oxidative stress and inflammation are major contributors to the pathogenesis and progression of AD. To date, available pharmacologic treatments are only symptomatic. Clinical trials focused on amyloid and non-amyloid-targeted treatments with small molecule pharmacotherapy and immunotherapies have accumulated a long list of failures. Considering that around 90 % of the circulating Aβ is bound to albumin, and that a dynamic equilibrium exists between peripheral and central Aβ, plasma exchange with albumin replacement has emerged as a new approach in a multitargeted AD therapeutic strategy (AMBAR Program). In plasma exchange, a patient’s plasma is removed by plasmapheresis to eliminate toxic endogenous substances, including Aβ and functionally impaired albumin. The fluid replacement used is therapeutic albumin, which acts not only as a plasma volume expander but also has numerous pleiotropic functions (e.g., circulating Aβ- binding capacity, transporter, detoxifier, antioxidant) that are clinically relevant for the treatment of AD. Positive results from the AMBAR Program (phase 1, 2, an 2b/3 trials), i.e., slower decline or stabilization of disease symptoms in the most relevant clinical efficacy and safety endpoints, offer a glimmer of hope to both AD patients and caregivers. 相似文献
998.
Puga Luís Teixeira Rogério Paiva Luís Ribeiro Joana Maria Gameiro João Sousa José Pedro Costa Marco Gonçalves Lino 《The international journal of cardiovascular imaging》2021,37(8):2359-2368
The International Journal of Cardiovascular Imaging - There is conflicting evidence regarding the significance of iatrogenic atrial septal defects (iASDs) after transseptal puncture during... 相似文献
999.
1000.
Gilles Montalescot Carlos Brotons Bernard Cosyns Harry J. Crijns Armando DAngelo Ludovic Drouet Franz Eberli Deirdre A. Lane Bruno Besse Anthony Chan Eric Vicaut Harald Darius 《Am J Cardiovasc Drugs》2020,20(1):61-71
Adherence to non-vitamin-K oral anticoagulants (NOACs) may be lower than to vitamin K antagonists because NOACs do not require routine monitoring. We assessed the impact of an educational program on adherence and persistence with apixaban in patients with non-valvular atrial fibrillation (NVAF). Patients with NVAF eligible for NOACs with one or more stroke risk factor (prior stroke/transient ischemic attack, age ≥ 75 years, hypertension, diabetes, or symptomatic heart failure) were randomized (1:1) to standard of care (SOC) or SOC with additional educational (information booklet, reminder tools, virtual clinic access). The primary outcome was adherence to apixaban (2.5 or 5 mg twice daily) at 24 weeks. Patients receiving the educational program were re-randomized (1:1) to continue the program for 24 further weeks or to switch to secondary SOC. Implementation adherence and persistence were reassessed at 48 weeks. In total, 1162 patients were randomized (SOC, 583; educational program, 579). Mean implementation adherence ± standard deviation (SD) at 24 weeks was 91.6% ± 17.1 for SOC and 91.9% ± 16.1 for the educational program arm; results did not differ significantly between groups at any time-point. At 48 weeks, implementation adherence was 90.4% ± 18.0, 90.1% ± 18.6, and 89.3% ± 18.1 for continued educational program, SOC, and secondary SOC, respectively; and corresponding persistence was 86.1% (95% confidence interval [CI] 81.3–89.7), 85.2% (95% CI 81.5–88.2), and 87.8% (95% CI 83.4–91.1). Serious adverse events were similar across groups. High implementation adherence and persistence with apixaban were observed in patients with NVAF receiving apixaban. The educational program did not show additional benefits. This study is registered at ClinicalTrials.gov [NCT01884350]. 相似文献